Molecular Therapies in Thyroid Cancer
AbstractThyroid cancer is a common diagnosis with greater than 34,000 cases per year in the United States. Early stage thyroid cancer is often managed with surgical intervention and radioactive iodine; however, for recurrent or metastatic disease, the treatment options, historically, have been limited to chemotherapy. Chemotherapy for metastatic thyroid cancer has been of limited efficacy. Encouragingly, molecular therapeutics have played a greater role in managing patients with advanced disease. These agents work primarily through disruption of tyrosine kinase pathways. This review will discuss the expanding role of molecular targets in managing patients with advanced thyroid cancer. View Full-Text
Scifeed alert for new publicationsNever miss any articles matching your research from any publisher
- Get alerts for new papers matching your research
- Find out the new papers from selected authors
- Updated daily for 49'000+ journals and 6000+ publishers
- Define your Scifeed now
Huyck, T.; Agulnik, M. Molecular Therapies in Thyroid Cancer. Pharmaceuticals 2011, 4, 91-100.
Huyck T, Agulnik M. Molecular Therapies in Thyroid Cancer. Pharmaceuticals. 2011; 4(1):91-100.Chicago/Turabian Style
Huyck, Timothy; Agulnik, Mark. 2011. "Molecular Therapies in Thyroid Cancer." Pharmaceuticals 4, no. 1: 91-100.